Mucopolysaccharidosis type II (MPS II) is an X-linked lysosomal storage disorder caused by pathogenic variants in the IDS gene encoding iduronate-2-sulfatase (IDS), which hydrolyzes sulfate groups in dermatan sulfate and heparan sulfate. The current treatment for MPS II includes enzyme replacement therapy and hematopoietic stem cell transplantation (HSCT). Both therapies have shown limited penetration through the blood-brain barrier. Anecdotal cases have been reported with the HSCT benefit to treat neurological problems in MPS II. Herein, we generated an MPS II mouse model using CRISPR/Cas9 to examine the effectiveness of CNS-directed, adeno-associated virus (AAV)2/9-mediated human IDS gene transfer in expressing sustained IDS and improving behavior performance in this model. The intracerebroventricular administration of AAV2/9-hIDS showed higher IDS activity in the central nervous system and better auditory function compared with those by intravenous administration. The results provide a strong proof of concept for the clinical translation of our approach to treating patients with MPS II and cognitive impairment.
Get full access to this article
View all access options for this article.
References
1.
HunterC. A Rare Disease in Two Brothers. Proc R Soc Med, 1917; 10(Sect Study Dis Child):104–116.
2.
ZapolnikP, PyrkoszA. Gene therapy for mucopolysaccharidosis type II—A review of the current possibilities. Int J Mol Sci, 2021; 22(11); doi: 10.3390/ijms22115490
3.
FesslováV, CortiP, SersaleG, et al.The natural course and the impact of therapies of cardiac involvement in the mucopolysaccharidoses. Cardiol Young, 2009; 19(2):170–178; doi: 10.1017/s1047951109003576
4.
StapletonM, KubaskiF, MasonRW, et al.Presentation and treatments for mucopolysaccharidosis type II (MPS II; Hunter Syndrome). Expert Opin Orphan Drugs, 2017; 5(4):295–307; doi: 10.1080/21678707.2017.1296761
5.
McBrideKL, FlaniganKM. Update in the Mucopolysaccharidoses. Semin Pediatr Neurol, 2021; 37:100874; doi: 10.1016/j.spen.2021.100874
6.
BaroneR, PellicoA, PittalàA, et al.Neurobehavioral phenotypes of neuronopathic mucopolysaccharidoses. Ital J Pediatr, 2018; 44(Suppl 2):121; doi: 10.1186/s13052-018-0561-2
7.
HorganC, JonesSA, BiggerBW, et al.Current and future treatment of mucopolysaccharidosis (MPS) Type II: Is brain-targeted stem cell gene therapy the solution for this devastating disorder? Int J Mol Sci, 2022; 23(9); doi: 10.3390/ijms23094854
8.
WangJ, LozierJ, JohnsonG, et al.Neutralizing antibodies to therapeutic enzymes: Considerations for testing, prevention and treatment. Nat Biotechnol, 2008; 26(8):901–908; doi: 10.1038/nbt.1484
9.
BiffiA. Hematopoietic stem cell gene therapy for storage disease: Current and new indications. Mol Ther, 2017; 25(5):1155–1162; doi: 10.1016/j.ymthe.2017.03.025
10.
SelvanathanA, EllawayC, WilsonC, et al.Effectiveness of early hematopoietic stem cell transplantation in preventing neurocognitive decline in mucopolysaccharidosis type II: A case series. JIMD Rep, 2018; 41:81–89; doi: 10.1007/8904_2018_104
11.
SonodaH, MorimotoH, YodenE, et al.A blood-brain-barrier-penetrating anti-human transferrin receptor antibody fusion protein for neuronopathic mucopolysaccharidosis II. Mol Ther, 2018; 26(5):1366–1374; doi: 10.1016/j.ymthe.2018.02.032
12.
OkuyamaT, EtoY, SakaiN, et al.Iduronate-2-Sulfatase with anti-human transferrin receptor antibody for neuropathic mucopolysaccharidosis II: A phase 1/2 trial. Mol Ther, 2019; 27(2):456–464; doi: 10.1016/j.ymthe.2018.12.005
13.
OkuyamaT, EtoY, SakaiN, et al.A Phase 2/3 trial of pabinafusp Alfa, IDS Fused with anti-human transferrin receptor antibody, targeting neurodegeneration in MPS-II. Mol Ther, 2021; 29(2):671–679; doi: 10.1016/j.ymthe.2020.09.039
FoustKD, NurreE, MontgomeryCL, et al.Intravascular AAV9 preferentially targets neonatal neurons and adult astrocytes. Nat Biotechnol, 2009; 27(1):59–65; doi: 10.1038/nbt.1515
16.
SmithMC, BelurLR, KarlenAD, et al.Comparative dose effectiveness of intravenous and intrathecal AAV9.CB7.hIDS, RGX-121, in mucopolysaccharidosis type II mice. Mol Ther Methods Clin Dev, 2024; 32(1):101201; doi: 10.1016/j.omtm.2024.101201
17.
LaoharaweeK, Podetz-PedersenKM, NguyenTT, et al.Non-invasive intravenous administration of AAV9 transducing iduronate sulfatase leads to global metabolic correction and prevention of neurologic deficits in a mouse model of Hunter syndrome. Mol Genet Metab Rep, 2023; 34:100956; doi: 10.1016/j.ymgmr.2023.100956
18.
RigonL, SalvalaioM, PederzoliF, et al.Targeting brain disease in MPSII: Preclinical evaluation of IDS-Loaded PLGA nanoparticles. Int J Mol Sci, 2019; 20(8); doi: 10.3390/ijms20082014
19.
LaoharaweeK, DeKelverRC, Podetz-PedersenKM, et al.Dose-Dependent prevention of metabolic and neurologic disease in murine MPS II by ZFN-Mediated In vivo genome editing. Mol Ther, 2018; 26(4):1127–1136; doi: 10.1016/j.ymthe.2018.03.002
20.
ChenN, EhmannDE, CrookerR, et al.Gene therapy for cross-correction of somatic organs and the CNS in mucopolysaccharidosis II in rodents and non-human primates. Mol Ther Methods Clin Dev, 2023; 29:286–302; doi: 10.1016/j.omtm.2023.03.014
21.
JansonCG, RomanovaLG, LeoneP, et al.Comparison of endovascular and intraventricular gene therapy with Adeno-Associated Virus-α-L-Iduronidase for hurler disease. Neurosurgery, 2014; 74(1):99–111; doi: 10.1227/neu.0000000000000157
22.
VoznyiYV, KeulemansJL, van DiggelenOP. A fluorimetric enzyme assay for the diagnosis of MPS II (Hunter disease). J Inherit Metab Dis, 2001; 24(6):675–680; doi: 10.1023/a:1012763026526
23.
MamczarzJ, LaneM, MerchenthalerI. Letrozole delays acquisition of water maze task in female BALB/c mice: Possible involvement of anxiety. Horm Behav, 2024; 162:105524; doi: 10.1016/j.yhbeh.2024.105524
24.
KraeuterAK, GuestPC, SarnyaiZ. The Y-Maze for assessment of spatial working and reference memory in mice. Methods Mol Biol, 2019; 1916:105–111; doi: 10.1007/978-1-4939-8994-2_10
25.
TanakaN, KidaS, KinoshitaM, et al.Evaluation of cerebrospinal fluid heparan sulfate as a biomarker of neuropathology in a murine model of mucopolysaccharidosis type II using high-sensitivity LC/MS/MS. Mol Genet Metab, 2018; 125(1–2):53–58; doi: 10.1016/j.ymgme.2018.07.013
26.
GarciaAR, PanJ, LamsaJC, et al.The characterization of a murine model of mucopolysaccharidosis II (Hunter syndrome). J Inherit Metab Dis, 2007; 30(6):924–934; doi: 10.1007/s10545-007-0641-8
27.
SmithMC, BelurLR, KarlenAD, et al.Generation and characterization of an immunodeficient mouse model of mucopolysaccharidosis type II. Mol Genet Metab, 2023; 138(4):107539; doi: 10.1016/j.ymgme.2023.107539
28.
LaoharaweeK, Podetz-PedersenKM, NguyenTT, et al.Prevention of neurocognitive deficiency in mucopolysaccharidosis type II mice by central nervous system-directed, AAV9-Mediated iduronate sulfatase gene transfer. Hum Gene Ther, 2017; 28(8):626–638; doi: 10.1089/hum.2016.184
29.
FuH, ZaraspeK, MurakamiN, et al.Targeting root cause by systemic scAAV9-hIDS Gene delivery: Functional correction and reversal of severe MPS II in mice. Mol Ther Methods Clin Dev, 2018; 10:327–340; doi: 10.1016/j.omtm.2018.07.005
30.
RathmannM, BungeS, BeckM, et al.Mucopolysaccharidosis type II (Hunter syndrome): mutation “hot spots” in the iduronate-2-sulfatase gene. Am J Hum Genet, 1996; 59(6):1202–1209.
31.
ZhangW, XieT, ShengH, et al.Genetic analysis of 63 Chinese patients with mucopolysaccharidosis type II: Functional characterization of seven novel IDS variants. Clin Chim Acta, 2019; 491:114–120; doi: 10.1016/j.cca.2019.01.009
32.
MashimaR, OhiraM, OkuyamaT, et al.A novel mucopolysaccharidosis type II mouse model with an iduronate-2-sulfatase-P88L mutation. Sci Rep, 2023; 13(1):7865; doi: 10.1038/s41598-023-34541-w
33.
MotasS, HaurigotV, GarciaM, et al.CNS-directed gene therapy for the treatment of neurologic and somatic mucopolysaccharidosis type II (Hunter syndrome). JCI Insight, 2016; 1(9):e86696; doi: 10.1172/jci.insight.86696
34.
HindererC, KatzN, LouboutinJP, et al.Delivery of an adeno-associated virus vector into cerebrospinal fluid attenuates central nervous system disease in mucopolysaccharidosis type II mice. Hum Gene Ther, 2016; 27(11):906–915; doi: 10.1089/hum.2016.101
35.
GraySJ, FotiSB, SchwartzJW, et al.Optimizing promoters for recombinant adeno-associated virus-mediated gene expression in the peripheral and central nervous system using self-complementary vectors. Hum Gene Ther, 2011; 22(9):1143–1153; doi: 10.1089/hum.2010.245
PolitoVA, CosmaMP. IDS crossing of the blood-brain barrier corrects CNS defects in MPSII mice. Am J Hum Genet, 2009; 85(2):296–301; doi: 10.1016/j.ajhg.2009.07.011
38.
DesnickRJ, SchuchmanEH. Enzyme replacement therapy for lysosomal diseases: Lessons from 20 years of experience and remaining challenges. Annu Rev Genomics Hum Genet, 2012; 13:307–335; doi: 10.1146/annurev-genom-090711-163739
39.
AhnJ, LeeJJ, ParkSI, et al.Auditory characteristics in patients with mucopolysaccharidosis. Otol Neurotol, 2019; 40(10):e955–e961; doi: 10.1097/mao.0000000000002422
40.
WolfbergJ, ChintalapatiK, TomatsuS, et al.Hearing loss in mucopolysaccharidoses: Current knowledge and future directions. Diagnostics (Basel), 2020; 10(8); doi: 10.3390/diagnostics10080554
41.
ChimeloFT, SilvaLAF, Neves-LoboIF, et al.Study of the peripheral and central auditory pathways in patients with mucopolysaccharidosis. J Commun Disord, 2024; 107:106402; doi: 10.1016/j.jcomdis.2023.106402
Supplementary Material
Please find the following supplemental material available below.
For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.
For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.
